Rocca, MA; Valsasina, P; Meani, A; Gobbi, C; Zecca, C; Rovira, À; Montalban, X; ... MAGNIMS Study Group; + view all Rocca, MA; Valsasina, P; Meani, A; Gobbi, C; Zecca, C; Rovira, À; Montalban, X; Kearney, H; Ciccarelli, O; Matthews, L; Palace, J; Gallo, A; Bisecco, A; Gass, A; Eisele, P; Lukas, C; Bellenberg, B; Barkhof, F; Vrenken, H; Preziosa, P; Comi, G; Filippi, M; MAGNIMS Study Group; - view fewer (2019) Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology 10.1212/WNL.0000000000008466. (In press).

	Text Ciccarelli NEUROLOGY-2018-951756.pdf - Accepted Version Access restricted to UCL open access staff Download (477kB)
	Text Ciccarelli NEUROLOGY-2018-951756-Online-Supplement.pdf - Accepted Version Access restricted to UCL open access staff Download (361kB)

Abstract

Objective To characterize the distribution and regional evolution of cervical cord atrophy in patients with multiple sclerosis (MS) in a multicenter dataset. Methods MRI and clinical evaluations were acquired from 179 controls and 435 patients (35 clinically isolated syndromes [CIS], 259 relapsing-remitting multiple sclerosis [RRMS], 99 secondary progressive multiple sclerosis [SPMS], and 42 primary progressive multiple sclerosis [PPMS]). Sixty-nine controls and 178 patients underwent a 1-year MRI and clinical follow-up. Patients were classified as clinically stable/worsened according to their disability change. Longitudinal changes of cord atrophy were investigated with linear mixed-effect models. Sample size calculations were performed using age-, sex- and site-adjusted annualized percentage normalized cord cross-sectional area (CSAn) changes. Results Baseline CSAn was lower in patients with MS vs controls (p < 0.001), but not different between controls and patients with CIS or between patients with early RRMS (disease duration ≤5 years) and patients with CIS. Patients with late RRMS (disease duration >5 years) showed significant cord atrophy vs patients with early RRMS (p = 0.02). Patients with progressive MS had decreased CSAn (p < 0.001) vs patients with RRMS. Atrophy was located between C1/C2 and C5 in patients with RRMS vs patients with CIS, and widespread along the cord in patients with progressive MS vs patients with RRMS, with an additional C5/C6 involvement in patients with SPMS vs patients with PPMS. At follow-up, CSAn decreased in all phenotypes (p < 0.001), except CIS. Cord atrophy rates were highest in patients with early RRMS and clinically worsened patients, who had a more widespread cord involvement than stable patients. The sample size per arm required to detect a 50% treatment effect was 118 for patients with early RRMS. Conclusions Cord atrophy increased in MS during 1 year, except for CIS. Faster atrophy contributed to explain clinical worsening.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item